NR1H3 and fatty liver disease: For example, Wouters et al. [68] demonstrated that pharmacologic LXRα activation, although it doubles hepatic steatosis, reverses hepatic inflammation in parallel with reversing hepatic cholesterol levels in a high-fat, high-cholesterol-induced NASH mouse model.